Showing 1 - 5 results of 5 for search 'Richard A Scolyer', query time: 0.01s Refine Results
  1. 1
    Lag-3 expression and clinical outcomes in metastatic melanoma patients treated with combination anti-lag-3 + anti-PD-1-based immunotherapies

    Lag-3 expression and clinical outcomes in metastatic melanoma patients treated with combination anti-lag-3 + anti-PD-1-based immunotherapies by Tuba N. Gide, Elizabeth C. Paver, Zarwa Yaseen, Nigel Maher, Nurudeen Adegoke, Alexander M. Menzies, Ines Pires da Silva, James S. Wilmott, Georgina V. Long, Richard A. Scolyer

    Published 2023-12-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Clinicopathological characteristics and management of colitis with anti-PD1 immunotherapy alone or in combination with ipilimumab

    Clinicopathological characteristics and management of colitis with anti-PD1 immunotherapy alone or in combination with ipilimumab by Serigne Lo, Georgina V Long, Richard A Scolyer, Matteo Carlino, Kazi J Nahar, Robert V Rawson, Tasnia Ahmed, Stephen Tattersall, Neomal Sandanayake, Christopher J Kiely, Umaimainthan Palendira, Alexander M Menzies

    Published 2020-10-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Impact of alternative diagnostic labels for melanoma in situ on management choices and psychological outcomes: protocol for an online randomised study

    Impact of alternative diagnostic labels for melanoma in situ on management choices and psychological outcomes: protocol for an online randomised study by Brooke Nickel, Lisa Parker, Jon Emery, Richard A Scolyer, Raymond Barnhill, David Elder, Katy JL Bell, Elspeth Davies, Blake O'Brien, Adewole S Adamson, Alexander C J van Akkooi, Farzaneh Boroumand, Zhuohan Wu, Peter M Ferguson, Donald Low, Cynthia Low, Sherrie Liu, Stacey Lewis, Bella Spongberg-Ross

    Published 2024-12-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial

    Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716... by Dirk Schadendorf, Caroline Robert, Reinhard Dummer, Luis de la Cruz-Merino, Paolo A Ascierto, John M Kirkwood, Georgina V Long, Jacek Mackiewicz, Richard A Scolyer, Piotr Rutkowski, Jean-Jacques Grob, Jason John Luke, Michele Del Vecchio, Mizuho Kalabis, Adnan Khattak, Matteo S Carlino, Yujie Zhao, Alexander Eggermont, Vanna Chiarion Sileni, Clemens Krepler

    Published 2024-03-01
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Interferon-gamma signature as prognostic and predictive marker in macroscopic stage III melanoma

    Interferon-gamma signature as prognostic and predictive marker in macroscopic stage III melanoma by Annegien Broeks, Michel W J M Wouters, Georgina V Long, Richard A Scolyer, Christian U Blank, Judith M Versluis, Karijn P M Suijkerbuijk, Petros Dimitriadis, Joyce Sanders, James S Wilmott, Alexander Maxwell Menzies, Yvonne M Schrage, Stephanie A Blankenstein, Robert Elens, Willeke A M Blokx, Winan van Houdt, Alexander C J van Akkooi

    Published 2024-04-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: